Thursday, October 01, 2009

Tape-Delay from the RMLSIC | That’s a Wrap!

The Rocky Mountain Life Science Investor Conference yielded a sense of sophistication and intensity catalyzed by the aggregation of high-quality presenting companies and top-tier venture and corporate investors. I was hardly surprised that then rumor, hearsay and innuendo combined to yield quite a bit of buzz throughout the oak paneled hallways of the Ritz Carlton about “interest”, “follow-on meetings”, and yes even “term sheets” and “syndicated deals”. Perhaps the most important take-away for this author is the continued realization that location in the obvious clusters is not a prerequisite for funding, rather great science and IP, great management and great market opportunity are the combined elements that often create opportunity for an entity when it goes shopping for an institutional round of financing.

We have previously covered the presenting companies:

Part I – The Diagnostic companies [HERE]
Part II – The Biopharma companies [HERE]
Part III – The Medical Device companies [HERE]

Here then is a list of those participating venture and corporate investors:

Venture Capital Funds

Corporate Investors
And to those individuals, associations and entities who made it all possible, a collective thank you and see you at the 2010 Rocky Mountain Life Science Investor Conference!

AZBio, Bowne & Co. (NYSE: BNE), Capital Advisors Group, Colorado Bioscience Association, Forest City Science + Technology Group, Cooley Godward Kronsih, Doresy & Whitney, Ernst & Young, Fitzsimons Redevelopment Authority, High Country Venture, inVentiv Clinical, Johnson & Johnson, Johnson & Johnson Development Corp., Montana Biosience Alliance, Morgenthaler Ventures, NMBio, Oklahoma Bioscience Association, PhRMA, Rocky Mountain Venture Capital Association, Sequel Venture Partners, Silicon Valley Bank, TriNet, Ubiquity, Utah Office of Economic Development and vSpring Capital.

No comments: